Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Peter Horby, Marion Mafham, Louise Linsell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 239

Showing 26-50 of 239 citing articles:

Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Hui Lin, Sanda Cho, Veeraraghavan Meyyur Aravamudan, et al.
Infection (2021) Vol. 49, Iss. 3, pp. 401-410
Open Access | Times Cited: 87
Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Sophie Juul, Emil Eik Nielsen, Joshua Feinberg, et al.
PLoS Medicine (2020) Vol. 17, Iss. 9, pp. e1003293-e1003293
Open Access | Times Cited: 84
Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients
Robert J. Ulrich, Andrea B. Troxel, Ellie Carmody, et al.
Open Forum Infectious Diseases (2020) Vol. 7, Iss. 10
Open Access | Times Cited: 69
De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning
Marcos V. Santana, Floriano Paes Silva
BMC Chemistry (2021) Vol. 15, Iss. 1
Open Access | Times Cited: 64
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study
Albert Prats‐Uribe, Anthony G. Sena, Lana Yin Hui Lai, et al.
BMJ (2021), pp. n1038-n1038
Open Access | Times Cited: 64
Real-time prediction of COVID-19 related mortality using electronic health records
Patrick Schwab, Arash Mehrjou, Sonali Parbhoo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 57
A Narrative Review of COVID-19 Vaccines
Barbaros Eroglu, Rina Fajri Nuwarda, Iqbal Ramzan, et al.
Vaccines (2021) Vol. 10, Iss. 1, pp. 62-62
Open Access | Times Cited: 54
Prevalence of Bacterial Coinfection and Patterns of Antibiotics Prescribing in Patients with COVID-19: A Systematic review and Meta-Analysis
Faisal Salman Alshaikh, Oula Nawaf Sindi, Brian Godman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 37
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
Philip L. Tzou, Kaiming Tao, Janin Nouhin, et al.
Viruses (2020) Vol. 12, Iss. 9, pp. 1006-1006
Open Access | Times Cited: 68
Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
Radha Rajasingham, Ananta Bangdiwala, Melanie R. Nicol, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 64
Combining Antivirals and Immunomodulators to Fight COVID-19
Vincent Feuillet, Bruno Canard, Alain Trautmann
Trends in Immunology (2020) Vol. 42, Iss. 1, pp. 31-44
Open Access | Times Cited: 58
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 56
Repurposing Antimalarials to Tackle the COVID-19 Pandemic
Sanjeev Krishna, Yolanda Augustin, Jigang Wang, et al.
Trends in Parasitology (2020) Vol. 37, Iss. 1, pp. 8-11
Open Access | Times Cited: 55
Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine
Bianza Moïse Bakadia, Feng He, Tiatou Souho, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 133, pp. 111008-111008
Open Access | Times Cited: 53
No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials”
Dr Subodh Kumar Pathak, Dr Abhijeet Ashok Salunke, Praveen Thivari, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 14, Iss. 6, pp. 1673-1680
Open Access | Times Cited: 51
Pathogenesis‐directed therapy of 2019 novel coronavirus disease
Charles W. Stratton, Yi‐Wei Tang, Hongzhou Lu
Journal of Medical Virology (2020) Vol. 93, Iss. 3, pp. 1320-1342
Open Access | Times Cited: 51
The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials
Kimberley Lewis, Dipayan Chaudhuri, Fayez Alshamsi, et al.
PLoS ONE (2021) Vol. 16, Iss. 1, pp. e0244778-e0244778
Open Access | Times Cited: 50
COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa
Bisi Bright, Chinedum P. Babalola, Nadia A. Sam‐Agudu, et al.
Globalization and Health (2021) Vol. 17, Iss. 1
Open Access | Times Cited: 50
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
Joel M. Gelfand, April W. Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 6, pp. 1704-1716
Open Access | Times Cited: 49
Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS‐CoV‐2
Abhishek Gour, Diksha Manhas, Swarnendu Bag, et al.
Phytotherapy Research (2021) Vol. 35, Iss. 8, pp. 4258-4283
Open Access | Times Cited: 46
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Sophie Juul, Emil Eik Nielsen, Joshua Feinberg, et al.
PLoS ONE (2021) Vol. 16, Iss. 3, pp. e0248132-e0248132
Open Access | Times Cited: 44
Can pharmaceutical drugs used to treat Covid-19 infection leads to human health risk? A hypothetical study to identify potential risk
Minashree Kumari, Arun Kumar
The Science of The Total Environment (2021) Vol. 778, pp. 146303-146303
Open Access | Times Cited: 40
Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review
Dena Zeraatkar, Tyler Pitre, Gareth Leung, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000309-e000309
Open Access | Times Cited: 32
An explanatory machine learning framework for studying pandemics: The case of COVID-19 emergency department readmissions
Behrooz Davazdahemami, Hamed M. Zolbanin, Dursun Delen
Decision Support Systems (2022) Vol. 161, pp. 113730-113730
Open Access | Times Cited: 31
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports
Adam Goldman, David Bomze, Rachel Dankner, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 3, pp. 1432-1442
Open Access | Times Cited: 48

Scroll to top